

# Manufacturing of Chlorhexidine Gluconate Solution







استثمر في عُمان  
Invest OMAN

# WHY OMAN



100% Ownership



Up to 10 Years Investor Residency



30 Years Tax Exemption



4th globally in quality of life index



No minimum capital



Market Access



Long Usufruct agreement



Free Trade Agreements with: USA, Singapore,  
South Korea & European Union




**MOODY'S**  
Ba1  
Stable outlook

**STANDARD  
& POOR'S**  
BB-  
Stable

**FitchRatings**  
BB+  
Stable outlook



## Sector Overview



Here is a visual comparison showing the 24.6% increase in healthcare investment from 2022 to 2023 in Oman, rising to over OMR 1 billion

**Import Dependency:** The health sector in Oman depends heavily on imported equipment and materials, with imports accounting for the majority of the estimated \$500 million spent annually on pharmaceutical products and medical equipment.

**Local Production Initiatives:** To reduce reliance on imports, Oman unveiled plans in 2020 to establish new pharmaceutical factories. The goal is to meet 20% of the sector's demand with local supply by the end of 2025 and as much as 50% by 2050

## Market Attractiveness

**Global Market 5.2%**

CAGR (2023–2033) in Manufacturing of Chlorhexidine Gluconate Solution

**USD 220 to 290 million**

Expected Market Size by 2032

**Governments and players involvement**

Active governments:



The key market players:





# Overview Opportunity

## Description

Chlorhexidine Gluconate is a widely used antiseptic, disinfectant, particularly in hospitals, and healthcare setting. It is commonly used for:

- Preoperative skin preparation
- Hand sanitizers and surgical scrubs
- Mouthwashes for oral care

## Rationale

- **Growing Healthcare Sector**

Oman is expanding healthcare infrastructure under its Vision 2040, boosting demand for medical supplies, including antiseptics like CHG.

Increased hospital beds, clinics, and surgical procedures drive continuous need for antiseptic solutions.

- **Import Dependency and Supply Security**

Currently, Oman imports most CHG solutions, mainly from India, creating vulnerability to supply disruptions. Local manufacturing would reduce import reliance, enhance supply chain resilience, and secure steady availability.

## Key indicators

### Total Investment Value

2,400,000 OMR

### Land Availability

10,000 sqm

### IRR

15%


### Project Capacity

2,387,000 OMR per year



## Demand Analysis

List of supplying markets for a product imported by Oman in 2024  
Product: 3004 Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses "incl. those for transdermal administration" or in forms or packings for retail sale (excl. goods of heading 3002, 3005 or 3006)





## Stakeholder's interaction and incentives

Sultanate of Oman سلطنة عُمان  
وزارة التجارة والصناعة وترويج الاستثمار  
Ministry of Commerce, Industry & Investment Promotion



الهيئة العامة للمناطق الاقتصادية الخاصة والمناطق الحرة  
Public Authority for Special Economic Zones and Free Zones  
Sultanate of Oman سلطنة عمان



وزارة الصحة  
Ministry of Health







## Contact Us

+968 8000 0222

[Info@investoman.om](mailto:Info@investoman.om)